A Cardiologist’s View of Hypoglycemia
- 119 Downloads
Recent studies have failed to show an improvement in cardiovascular mortality with intensive glycemic control and aggressive glycated hemoglobin (A1c) targets less than 7.0%. Excessive hypoglycemic episodes with intensive glucose-lowering therapy are thought to be a major factor in the failure to show cardiovascular benefit in these trials. In this article, we review the physiology of glucose metabolism, the cardiovascular pathophysiology of hypoglycemia, and the trials with an intensive glucose-lowering strategy that have studied microvascular and macrovascular complications. We also review the current non-insulin drugs available for the treatment of diabetes and their potential hypoglycemic and cardiovascular impacts.
KeywordsDiabetes Hypoglycemia Cardiology
No potential conflicts of interest relevant to this article were reported.
Papers of particular interests, published recently, have been highlighted as: • Of importance
- 1.Cryer PE: Hypoglycemia. Pathophysiology, Diagnosis, and Treatment. New York: Oxford University Press; 1997.Google Scholar
- 9.• Patterson B; Fields AV, Richard S: New insights into myocardial glucose metabolism: surviving under stress. Curr Opin Clin Nutr Metab Care 2009, 12:424–430. This article points out many important metabolic changes in myocardial metabolism during stress.Google Scholar
- 14.Euler U, Liljestrand G, Skandinav D: Die Wirkung des adrenalins auf das minutenvolumen des herzens beim menschen [German]. Arch Physiol 1927, 52:243.Google Scholar
- 18.Ziegler D: Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Rev 1999, 7:300–315.Google Scholar
- 19.Vinik SI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy Diabetes Care 2003, 26:1553–1579.Google Scholar
- 21.• Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559. This is an important trial in regard to increased cardiovascular events in the intensive-treatment arm and increased hypoglycemic events overall.Google Scholar
- 22.• ADVANCE Collaborative Group, Patel A, MacMahon S, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572. This is a recent pivotal trial that looked at cardiovascular outcomes with intensive glucose-lowering therapy.Google Scholar
- 23.• Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139. This is an important trial with the additional concern of weight gain and hypoglycemia with increasing insulin.Google Scholar
- 36.Skyler JS, Bergenstal R, Bonow RO, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009, 53:298–304.CrossRefPubMedGoogle Scholar